Loading
companiesCompany
Alphamab Oncology
Alphamab developed envafolimab, the first subcutaneous PD-L1 antibody approved anywhere, and the HER2 bispecific ADC JSKN003.
Also called: 康宁杰瑞Jiangsu Alphamab BiopharmaceuticalsAlphamab Oncology
Overview
Alphamab Oncology, based in Suzhou, founded in 2008 and listed in Hong Kong as 9966.HK, developed envafolimab, the first subcutaneous PD-L1 antibody approved anywhere, and the HER2 bispecific ADC JSKN003. Envafolimab, sold as Enweida, was approved in 2021; KN026, a HER2 biparatopic bispecific, is in phase 3 in gastric and breast cancer; and JSKN003 and JSKN033, a subcutaneous PD-L1 plus HER2 ADC combination, are in trials, all built on its single-domain antibody platform. OnCo links it to HER2 and PD-L1 as targets and to the envafolimab record. Whether subcutaneous dosing wins meaningful share in a class dominated by intravenous antibodies is the open question. Envafolimab has its own page.
Headquarters
Suzhou, CN
Scorecard
All companies#151of 1244 companies, score 39
- approved products +6
- phase 3 +6
- targets +2
- modalities +4
- regions +1
- registry trials +20
1 approved, 2 in phase 3, 0 earlier, 1 targets, 103 registry studies. Formula on the scorecards page.
Type
Biotech · 9966.HK
Stage
Public
Website
Founded
2008
ApprovedSingle-domain antibody (anti-PD-L1, subcutaneous)
Envafolimab · Enweida
Envafolimab is the first PD-L1 antibody given as a quick injection under the skin rather than an infusion, approved in China for advanced tumours with mismatch-repair deficiency.
Phase 3antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record
JSKN003 is an experimental investigational agent whose form is not stated in the registry from Jiangsu Alphamab Biopharmaceuticals in phase 3 trials for HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, with its target not yet stated publicly.
Phase 3antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record
JSKN016 is an experimental investigational agent whose form is not stated in the registry from Jiangsu Alphamab Biopharmaceuticals in phase 3 trials for triple-negative breast cancer and HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.
Similar pages
- TreatmentSugemalimab
Shares PD-L1 and the tag china.
- CompanyCSPC Pharmaceutical Group
Shares JSKN003 and the tag china.
- TreatmentAdebrelimab
Shares PD-L1 and the tag china.
- TreatmentInetetamab
Shares HER2 and the tag china.
- TreatmentBenmelstobart
Shares PD-L1 and the tag china.
- TreatmentIparomlimab and tuvonralimab
Shares PD-L1 and the tag china.
- TrialKN035 for dMMR/MSI-H Advanced Solid Tumors
Shares 3D Medicines, Envafolimab.
- TrialENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
Shares 3D Medicines, Envafolimab.
fronts
targets
drugs
ApprovedSingle-domain antibody (anti-PD-L1, subcutaneous)
Envafolimab · Enweida
Phase 3antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record
Phase 3antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record
companies
trials
A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung CancerA Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of CareEvaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical StudyJSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer SubjectsSafety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid TumorsStudy of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer